🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

18,99 USD

Máx. histórico

178,74

2143 días

Split 1:6 del 12/07/2012

Caída desde máximo

-89,38%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+2,43%

Cierre anterior

18,54

Rango de hoy

18,52 – 19,26

Volumen hoy

1.328.200

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 22 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
29/01/2001 34,69 42,00 34,50 37,50 +9,89% 21,62% 29.367
26/01/2001 34,13 34,50 32,63 34,13 +3,41% 5,49% 9.233
25/01/2001 33,66 34,13 32,25 33,00 -0,56% 5,57% 6.583
24/01/2001 33,75 35,25 33,00 33,19 +0,57% 6,67% 12.383
23/01/2001 31,88 33,00 31,50 33,00 +2,33% 4,71% 5.283
22/01/2001 31,50 32,25 30,38 32,25 +2,38% 5,95% 13.450
19/01/2001 31,88 32,63 30,38 31,50 +1,20% 7,06% 8.900
18/01/2001 31,41 32,63 31,13 31,13 +0,00% 4,78% 6.983
17/01/2001 32,63 33,75 30,56 31,13 -3,49% 9,77% 20.167
16/01/2001 33,28 33,38 31,50 32,25 +0,00% 5,63% 13.100
12/01/2001 33,00 34,13 31,88 32,25 -2,27% 6,82% 16.233
11/01/2001 30,38 33,75 29,25 33,00 +7,32% 14,81% 12.217
10/01/2001 27,56 30,75 27,19 30,75 +6,49% 12,93% 11.667
09/01/2001 27,00 28,88 26,44 28,88 +6,94% 9,03% 7.833
08/01/2001 29,25 29,63 25,88 27,00 -4,00% 12,82% 11.467
05/01/2001 32,25 32,25 28,03 28,13 -11,76% 13,08% 16.367
04/01/2001 31,88 32,81 30,00 31,88 +3,66% 8,82% 29.517
03/01/2001 25,97 30,75 24,00 30,75 +18,84% 25,99% 39.100
02/01/2001 28,50 28,50 24,94 25,88 -9,21% 12,50% 8.233
29/12/2000 25,69 30,00 24,75 28,50 +10,95% 20,44% 49.150
28/12/2000 24,66 27,38 24,38 25,69 +5,38% 12,17% 28.133
27/12/2000 24,47 26,06 24,00 24,38 -5,11% 8,43% 31.567
26/12/2000 24,75 25,69 21,94 25,69 -2,14% 15,15% 36.933
22/12/2000 28,13 28,50 21,75 26,25 -1,41% 24,00% 51.983
21/12/2000 29,25 29,81 26,25 26,63 -8,97% 12,18% 23.367
20/12/2000 25,50 31,50 25,31 29,25 -14,29% 24,26% 43.283
19/12/2000 35,06 36,00 33,38 34,13 -3,19% 7,49% 26.383
18/12/2000 38,06 38,25 34,31 35,25 -7,84% 10,34% 32.017
15/12/2000 41,25 41,25 36,00 38,25 -4,67% 12,73% 21.167
14/12/2000 40,88 41,63 39,75 40,13 -3,17% 4,59% 7.767